Skip to main content

Table 4 Univariate analysis of the influence of genetic polymorphisms on the occurrence of AEs

From: Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease

SNP

EDS and sleep attacks

Visual hallucinations

Nausea and vomiting

Orthostatic hypotension

OR (95% CI)

p value

OR (95% CI)

p value

OR (95% CI)

p value

OR (95% CI)

p value

NLRP3 rs35829419

0.70 (0.30–1.68)

0.430

0.77 (0.30–2.00)

0.593

0.77 (0.31–1.91)

0.570

0.76 (0.33–1.76)

0.520

CARD8 rs2043211

0.856 (0.50–1.48)

0.581

0.80 (0.44–1.45)

0.457

1.27 (0.71–2.27)

0.414

1.01(0.59–1.74)

0.961

IL1β* rs16944

1.25 (0.72–2.16)

0.435

1.31 (0.72–2.40)

0.380

0.72 (0.41–1.29)

0.273

0.69 (0.40–1.18)

0.173

IL1β rs1143623

1.19 (0.69–2.08)

0.532

1.13 (0.61–2.07)

0.702

0.73 (0.40–1.32)

0.295

0.57 (0.32–1.00)

0.050

TNF-α rs1800629

0.83 (0.45–1.52)

0.547

0.78 (0.40–1.54)

0.477

0.83 (0.44–1.57)

0.559

0.98 (0.54–1.77)

0.943

IL6 rs1800795

0.90 (0.50–1.65)

0.740

0.67 (0.35–1.27)

0.218

1.23 (0.64–2.36)

0.529

1.34 (0.73–2.48)

0.343

NOS1 rs2293054

1.33 (0.77–2.30)

0.312

1.02 (0.56–1.86)

0.960

0.84 (0.50–1.49)

0.542

0.82 (0.48–1.42)

0.480

NOS1 rs2682826

1.75 (1.00–3.06)

0.048

1.25 (0.68–2.29)

0.471

0.58 (0.32–1.03)

0.064

1.02 (0.60–1.76)

0.933

GPX1 rs1050450

1.13 (0.65–1.96)

0.663

1.79 (0.97–3.31)

0.061

0.63 (0.35–1.13)

0.124

0.92 (0.54–1.59)

0.770

CAT rs10836235

1.08 (0.56–2.05)

0.827

1.65 (0.84–3.26)

0.150

1.58 (0.82–3.05)

0.174

1.84 (0.98–3.47)

0.059

CAT rs1001179

1.00 (0.58–1.74)

0.994

0.75 (0.41–1.37)

0.345

0.76 (0.42–1.36)

0.348

0.90 (0.52–1.55)

0.693

SOD2 rs4880

1.20 (0.65–2.22)

0.554

0.96 (0.50–1.85)

0.896

0.51 (0.28–0.94)

0.030

1.26 (0.69–2.31)

0.450

SNP

Peripheral edema

Impulse control disorders

Motor fluctuations

Dyskinesia

NLRP3 rs35829419

0.87 (0.31–2.43)

0.790

0.69 (0.20–2.42)

0.559

0.74 (0.33–1.63)

0.449

0.96 (0.43–2.14)

0.919

CARD8 rs2043211

0.60 (0.31–1.17)

0.133

0.55 (0.26–1.17)

0.122

0.92 (0.54–1.55)

0.744

1.33 (0.78–2.23)

0.288

IL1β* rs16944

0.60 (0.31-1.17)

0.133

1.72 (0.80–3.71)

0.167

1.11 (0.66–1.87)

0.700

1.09 (0.64–1.84)

0.762

IL1β rs1143623

0.59 (0.29–1.19)

0.140

1.10 (0.52–2.35)

0.800

1.13 (0.66–1.92)

0.665

1.28 (0.75–2.19)

0.366

TNF-α rs1800629

0.85 (0.41–1.76)

0.655

1.74 (0.80–3.76)

0.162

1.08 (0.61–1.91)

0.799

1.11 (0.63–1.97)

0.714

IL6 rs1800795

0.95 (0.46–1.96)

0.890

0.87 (0.39–1.95)

0.731

0.62 (0.34–1.11)

0.108

0.80 (0.45–1.43)

0.447

NOS1 rs2293054

1.45 (0.75–2.82)

0.270

0.99 (0.47–2.10)

0.979

1.05 (0.62–1.78)

0.854

0.73 (0.43–1.24)

0.238

NOS1 rs2682826

1.43 (0.73–2.79)

0.296

1.93 (0.88–4.22)

0.100

0.89 (0.53–1.51)

0.663

0.82 (0.48–1.39)

0.459

GPX1 rs1050450

0.75 (0.39–1.46)

0.400

0.79 (0.37–1.67)

0.531

1.55 (0.92–2.63)

0.103

1.18 (0.70–2.01)

0.533

CAT rs10836235

0.70 (0.30–1.63)

0.410

1.39 (0.60–3.23)

0.446

1.15 (0.62–2.14)

0.663

1.39 (0.75–2.59)

0.301

CAT rs1001179

0.32 (0.15–0.68)

0.003

0.67 (0.31–1.45)

0.314

0.92 (0.54–1.55)

0.750

1.28 (0.75–2.18)

0.362

SOD2 rs4880

0.75 (0.37–1.52)

0.422

0.89 (0.40–2.00)

0.777

1.25 (0.70–2.22)

0.456

1.04 (0.58–1.86)

0.897

  1. Significant and nominally significant results are written in bold text. Homozygotes for wild-type alleles were used as reference, except for one SNP
  2. *Recessive model was used